GILDGILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 69.57 $ -1.12 (-1.58 %)    

Tuesday, 25-Jun-2024 15:59:56 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 69.61
$ 70.65
$ 69.52 x 302
$ 71.94 x 300
$ 69.53 - $ 71.43
$ 61.32 - $ 85.92
8,354,538
na
86.8B
$ 0.33
$ 178.98
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 02-27-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-24-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-25-2015 12-31-2014 10-K
39 11-05-2014 09-30-2014 10-Q
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 draftkings-and-dell-were-among-the-10-biggest-large-cap-stock-gainers-last-week-june-16-june-22-are-these-in-your-portfolio

Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKN...

 nvidia-snaps-8-week-winning-run-sp-500-marks-longest-streak-without-a-2-drop-since-great-recession-oil-prices-stage-comeback-this-week-in-the-market

Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concer...

 gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

 why-gilead-sciences-stock-is-trading-higher-friday

On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir.

 sp-500-nasdaq-100-dip-from-record-highs-as-investors-take-chipmaker-profits-energy-sector-rebounds-yields-rise-whats-driving-markets-thursday

After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declin...

 baird-maintains-neutral-on-gilead-sciences-maintains-80-price-target

Baird analyst Brian Skorney maintains Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $80 price target.

 why-is-gilead-sciences-stock-trading-higher-on-thursday

Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in p...

 gilead-announces-results-from-interim-analysis-of-phase-3-trial-lenacapavir-showed-100-efficacy-for-hiv-prevention-shows-superiority-to-daily-truvada

-Bloomberg

 detailed-data-from-gilead-halted-blood-cancer-drug-magrolimab-program-shows-higher-deaths-and-side-effects

Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with...

 rbc-capital-reiterates-sector-perform-on-gilead-sciences-maintains-74-price-target

RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:GILD) with a Sector Perform and maintains $74 price ta...

 gileads-kite-revealed-new-data-on-yescarta-and-tecartus-outpatient-administration-at-eha-2024

– Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduc...